Nemonapride: Difference between revisions
Appearance
Content deleted Content added
Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'DrugBank_Ref', 'ChEBI_Ref') per [[Wikipedia:WikiProject Chemicals/Chembox vali |
More detail in short description |
||
(25 intermediate revisions by 19 users not shown) | |||
Line 1: | Line 1: | ||
{{short description|Antipsychotic medication}} |
|||
{{drugbox |
|||
{{Additional citations|date=July 2022}} |
|||
{{Drugbox |
|||
⚫ | |||
⚫ | |||
⚫ | |||
| width = 240 |
|||
<!--Clinical data--> |
|||
| tradename = Emilace (<small>[[Japan|JP]]</small>) |
|||
| Drugs.com = {{drugs.com|international|nemonapride}} |
|||
⚫ | |||
| legal_status = Rx-only (<small>[[Japan|JP]]</small>) |
|||
⚫ | |||
<!--Pharmacokinetic data--> |
|||
⚫ | |||
⚫ | |||
⚫ | |||
| excretion = |
|||
<!--Identifiers--> |
|||
| IUPHAR_ligand = 983 |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| UNII_Ref = {{fdacite|correct|FDA}} |
| UNII_Ref = {{fdacite|correct|FDA}} |
||
| UNII = Q88T5P3444 |
| UNII = Q88T5P3444 |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| KEGG_Ref = {{keggcite|correct|kegg}} |
| KEGG_Ref = {{keggcite|correct|kegg}} |
||
| KEGG = D01468 |
| KEGG = D01468 |
||
| ChemSpiderID = 4297 |
|||
| C = 21 | H = 26 | Cl = 1 | N = 3 | O = 2 |
|||
| ChEBI = 64217 |
|||
| molecular_weight = 387.90 g/mol |
|||
| ChEMBL = 20734 |
|||
⚫ | |||
| PDB_ligand = AQD |
|||
⚫ | |||
⚫ | |||
<!--Chemical data--> |
|||
⚫ | |||
| |
| = |
||
⚫ | |||
⚫ | |||
| StdInChI = 1S/C21H26ClN3O2/c1-14-18(9-10-25(14)13-15-7-5-4-6-8-15)24-21(26)16-11-17(22)19(23-2)12-20(16)27-3/h4-8,11-12,14,18,23H,9-10,13H2,1-3H3,(H,24,26) |
|||
| legal_status = Rx-only |
|||
| StdInChIKey = KRVOJOCLBAAKSJ-UHFFFAOYSA-N |
|||
⚫ | |||
}} |
}} |
||
'''Nemonapride''' ('''Emilace''') is |
'''Nemonapride''' ('''Emilace''') is [[atypical antipsychotic]] approved in [[Japan]] for the treatment of [[schizophrenia]]. It was launched by [[Yamanouchi Pharmaceutical|Yamanouchi]] in 1991. Nemonapride acts as a [[D2 receptor|D<sub>2</sub>]] and [[D3 receptor|D<sub>3</sub> receptor]] [[receptor_antagonist|antagonist]], and is also a potent [[5-HT1A_receptor|5-HT<sub>1A</sub> receptor]] agonist. It has affinity for [[Sigma_receptor|sigma receptors]]. |
||
== See also == |
== See also == |
||
* [[Typical antipsychotic]] |
|||
* [[Benzamide]] |
* [[Benzamide]] |
||
== References == |
== References == |
||
{{Reflist |
{{Reflist}} |
||
{{Unreferenced|date=November 2009}} |
|||
{{Antipsychotics}} |
{{Antipsychotics}} |
||
{{Navboxes |
|||
{{Dopaminergics}} |
|||
| title = [[Pharmacodynamics]] |
|||
| titlestyle = background:#ccccff |
|||
| list1 = |
|||
{{Dopamine receptor modulators}} |
|||
{{Serotonin receptor modulators}} |
|||
{{Sigma receptor modulators}} |
|||
}} |
|||
[[Category: |
[[Category:]] |
||
[[Category:Benzamides]] |
[[Category:Benzamides]] |
||
[[Category:Chloroarenes]] |
|||
[[Category:Phenol ethers]] |
[[Category:Phenol ethers]] |
||
[[Category: |
[[Category:]] |
||
{{nervous-system-drug-stub}} |
{{nervous-system-drug-stub}} |
||
[[ja:ネモナプリド]] |